Back to Search
Start Over
The role of osteoanabolic agents in the management of patients with osteoporosis.
- Source :
- Postgraduate Medicine; Aug2022, Vol. 134 Issue 6, p541-551, 11p
- Publication Year :
- 2022
-
Abstract
- Reducing fracture risk is the objective of osteoporosis treatment. Bone-forming osteoporosis drugs increase bone mass, restore bone microarchitecture, and reduce fracture risk more effectively than oral bisphosphonates, providing strong justification for the use of these agents as the initial therapy or after anti-remodeling agents in patients at very high risk of fracture. At the end of a 12-to-24-month course of osteoanabolic therapy, transitioning to a potent anti-remodeling agent maintains and enhances the treatment benefit. This review describes the clinical applications of osteoanabolic therapy for osteoporosis. [ABSTRACT FROM AUTHOR]
- Subjects :
- OSTEOPOROSIS
CLINICAL medicine
Subjects
Details
- Language :
- English
- ISSN :
- 00325481
- Volume :
- 134
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- Postgraduate Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 158696686
- Full Text :
- https://doi.org/10.1080/00325481.2022.2069582